search
Back to results

Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
metformin placebo
linagliptin placebo
metformin
metformin
linagliptin
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  1. Diagnosis of Type 2 diabetes mellitus (T2DM) prior to informed consent;
  2. Male and female patients on diet and exercise regimen who are drug naive, defined as absence of any oral antidiabetic therapy or insulin for 12 weeks prior to randomization
  3. Glycosylated haemoglobin A1c (HbA1c) >/= 7.0% (53 mmol/mol) to </= 10.0% (86 mmol/mol) at visit 1 (screening);
  4. Age>/=18 and </=80 years at visit 1(screening);
  5. Body Mass Index (BMI)</= 45kg/m2 at visit 1 (screening);
  6. Signed and dated written informed consent by date of visit 1 in accordance with Good Clinical Practice (GCP) and local legislation

Exclusion criteria:

  1. Uncontrolled hyperglycaemia with a glucose level >240 mg/dl (13.3mmol/L) after an overnight fast during screening/placebo run-in and confirmed by a second measurement (Not on the same day);
  2. Treatment with any oral antidiabetic drug or insulin within 12 weeks prior to randomization
  3. Acute coronary syndrome (non-STEMI, STEMI and unstable angina pectoris),stroke or Transient ischemia attack (TIA) within 3 months prior to informed consent;
  4. Indication of liver disease/Impaired hepatic function, defined by serum levels of either Aspartate aminotransferase (ALT or SGPT), alanine aminotransferase (AST or SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at visit 1 and/or run-in phase,
  5. Impaired renal function, defined as eGFR< 60ml/min (moderate or severe renal impairment, modification of diet in renal disease (MDRD) formula) as determined during screening or at run-in phase
  6. Bariatric surgery within the past two years and other gastrointestinal surgeries that induced chronic malabsorption
  7. Medical history of Cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years
  8. Blood dyscrasia or any other disorders causing haemolysis or unstable Red Blood Cell (eg. malaria, babesiosis, haemolytic anemia)
  9. Known history of pancreatitis and chronic pancreatitis
  10. Contraindications to metformin according to the local label
  11. Treatment with anti-obesity drugs 3 months prior to informed consent or any other treatment at the time of screening (i.e. surgery, aggressive diet regimen etc) leading to unstable body weight
  12. Current treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent or any other uncontrolled endocrine disorder except T2DM
  13. Pre-menopausal women (last menstruation less than 1 year prior to informed consent) who:

    1. are nursing or pregnant or
    2. are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial or who do not agree to continue contraception for at least 30 days after the last dose of study drug. Acceptable methods of birth control include tubal ligation, transdermal patch, intra-uterine devices/systems(IUDs/IUSs), oral, implantable, or injectable contraceptives, complete sexual abstinence (if acceptable by local authorities), double barrier method and vasectomized partner.
  14. Alcohol or drug abuse within 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study drug intake
  15. Participation in another trial with application of any investigational drug within 30 days prior to informed consent
  16. Any other clinical condition that would jeopardize patients safety while participating in this trial

Sites / Locations

  • 1218.60.90001 Boehringer Ingelheim Investigational Site
  • 1218.60.90002 Boehringer Ingelheim Investigational Site
  • 1218.60.90003 Boehringer Ingelheim Investigational Site
  • 1218.60.32001 Boehringer Ingelheim Investigational Site
  • 1218.60.32005 Boehringer Ingelheim Investigational Site
  • 1218.60.32002 Boehringer Ingelheim Investigational Site
  • 1218.60.32004 Boehringer Ingelheim Investigational Site
  • 1218.60.32003 Boehringer Ingelheim Investigational Site
  • 1218.60.20009 Boehringer Ingelheim Investigational Site
  • 1218.60.20003 Boehringer Ingelheim Investigational Site
  • 1218.60.20014 Boehringer Ingelheim Investigational Site
  • 1218.60.20010 Boehringer Ingelheim Investigational Site
  • 1218.60.20004 Boehringer Ingelheim Investigational Site
  • 1218.60.20012 Boehringer Ingelheim Investigational Site
  • 1218.60.20015 Boehringer Ingelheim Investigational Site
  • 1218.60.20006 Boehringer Ingelheim Investigational Site
  • 1218.60.20013 Boehringer Ingelheim Investigational Site
  • 1218.60.20002 Boehringer Ingelheim Investigational Site
  • 1218.60.20011 Boehringer Ingelheim Investigational Site
  • 1218.60.20005 Boehringer Ingelheim Investigational Site
  • 1218.60.20007 Boehringer Ingelheim Investigational Site
  • 1218.60.20016 Boehringer Ingelheim Investigational Site
  • 1218.60.20001 Boehringer Ingelheim Investigational Site
  • 1218.60.86001 Boehringer Ingelheim Investigational Site
  • 1218.60.86003 Boehringer Ingelheim Investigational Site
  • 1218.60.86011 Boehringer Ingelheim Investigational Site
  • 1218.60.86012 Boehringer Ingelheim Investigational Site
  • 1218.60.86010 Boehringer Ingelheim Investigational Site
  • 1218.60.86013 Boehringer Ingelheim Investigational Site
  • 1218.60.86014 Boehringer Ingelheim Investigational Site
  • 1218.60.86006 Boehringer Ingelheim Investigational Site
  • 1218.60.86007 Boehringer Ingelheim Investigational Site
  • 1218.60.86005 Boehringer Ingelheim Investigational Site
  • 1218.60.86009 Boehringer Ingelheim Investigational Site
  • 1218.60.86008 Boehringer Ingelheim Investigational Site
  • 1218.60.49007 Boehringer Ingelheim Investigational Site
  • 1218.60.49008 Boehringer Ingelheim Investigational Site
  • 1218.60.49005 Boehringer Ingelheim Investigational Site
  • 1218.60.49004 Boehringer Ingelheim Investigational Site
  • 1218.60.49006 Boehringer Ingelheim Investigational Site
  • 1218.60.49003 Boehringer Ingelheim Investigational Site
  • 1218.60.49002 Boehringer Ingelheim Investigational Site
  • 1218.60.49001 Boehringer Ingelheim Investigational Site
  • 1218.60.50001 Boehringer Ingelheim Investigational Site
  • 1218.60.50002 Boehringer Ingelheim Investigational Site
  • 1218.60.50003 Boehringer Ingelheim Investigational Site
  • 1218.60.85001 Boehringer Ingelheim Investigational Site
  • 1218.60.85002 Boehringer Ingelheim Investigational Site
  • 1218.60.91004 Boehringer Ingelheim Investigational Site
  • 1218.60.91010 Boehringer Ingelheim Investigational Site
  • 1218.60.91005 Boehringer Ingelheim Investigational Site
  • 1218.60.91008 Boehringer Ingelheim Investigational Site
  • 1218.60.91001 Boehringer Ingelheim Investigational Site
  • 1218.60.91007 Boehringer Ingelheim Investigational Site
  • 1218.60.91003 Boehringer Ingelheim Investigational Site
  • 1218.60.91006 Boehringer Ingelheim Investigational Site
  • 1218.60.96001 Boehringer Ingelheim Investigational Site
  • 1218.60.96002 Boehringer Ingelheim Investigational Site
  • 1218.60.96004 Boehringer Ingelheim Investigational Site
  • 1218.60.96003 Boehringer Ingelheim Investigational Site
  • 1218.60.96005 Boehringer Ingelheim Investigational Site
  • 1218.60.52005 Boehringer Ingelheim Investigational Site
  • 1218.60.52003 Boehringer Ingelheim Investigational Site
  • 1218.60.52001 Boehringer Ingelheim Investigational Site
  • 1218.60.52002 Boehringer Ingelheim Investigational Site
  • 1218.60.52004 Boehringer Ingelheim Investigational Site
  • 1218.60.51001 Boehringer Ingelheim Investigational Site
  • 1218.60.51002 Boehringer Ingelheim Investigational Site
  • 1218.60.51004 Boehringer Ingelheim Investigational Site
  • 1218.60.63001 Boehringer Ingelheim Investigational Site
  • 1218.60.63004 Boehringer Ingelheim Investigational Site
  • 1218.60.63003 Boehringer Ingelheim Investigational Site
  • 1218.60.63002 Boehringer Ingelheim Investigational Site
  • 1218.60.63005 Boehringer Ingelheim Investigational Site
  • 1218.60.34001 Boehringer Ingelheim Investigational Site
  • 1218.60.34002 Boehringer Ingelheim Investigational Site
  • 1218.60.34003 Boehringer Ingelheim Investigational Site
  • 1218.60.34004 Boehringer Ingelheim Investigational Site
  • 1218.60.34006 Boehringer Ingelheim Investigational Site
  • 1218.60.34005 Boehringer Ingelheim Investigational Site
  • 1218.60.34009 Boehringer Ingelheim Investigational Site
  • 1218.60.34008 Boehringer Ingelheim Investigational Site
  • 1218.60.34007 Boehringer Ingelheim Investigational Site
  • 1218.60.34010 Boehringer Ingelheim Investigational Site
  • 1218.60.88006 Boehringer Ingelheim Investigational Site
  • 1218.60.88003 Boehringer Ingelheim Investigational Site
  • 1218.60.88001 Boehringer Ingelheim Investigational Site
  • 1218.60.88007 Boehringer Ingelheim Investigational Site
  • 1218.60.88002 Boehringer Ingelheim Investigational Site
  • 1218.60.88004 Boehringer Ingelheim Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

linagliptin + metformin

metformin

Arm Description

patients to receive linagliptin +metformin QD

patients to receive metformin BID

Outcomes

Primary Outcome Measures

Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) After 14 Weeks Treatment
Adjusted mean change in HbA1c from baseline at Week 14 was analysed using an ANCOVA model. The Model included treatment and continuous baseline HbA1c.

Secondary Outcome Measures

Composite Endpoint of Occurrence of Treat to Target Efficacy Response, That is an HbA1c Under Treatment of <7.0% After 14 Weeks of Treatment, on no Occurrence of Moderate or Severe Gastrointestinal (GI) Side Effects During 14 Weeks of Treatment
The proportion of patients who achieved all the targets in a composite endpoint (HbA1c below 7.0% after 14 weeks of treatment; no occurrence of pre-specified moderate or severe gastrointestinal (GI) side effects of metformin, as assessed by the investigators during 14 weeks of treatment)
Occurence of Metformin Pre-specified Moderate to Severe GI Side Effects Assessed by Investigators During 14 Weeks of Treatment
Proportion of patients who experienced at least one metformin pre-specified moderate or severe GI side effect during 14 weeks
Change From Baseline in Fasting Plasma Glucose (FPG) After 14 Weeks of Treatment
Means are adjusted by treatment, continuous baseline HbA1c and continuous baseline fasting plasma glucose.
Metformin Pre-specified GI Symptom Intensity Score Assessed by Investigators During 14 Weeks of Treatment
Patients could experience multiple events, therefore, multiple answers were possible for each patient.
Metformin Pre-specified GI Symptom Intensity Score Assessed by Patients During 14 Weeks of Treatment
The intensity of the GI side effects was also assessed by the patients using VAS scaled from 0 to 10; higher scores indicate more severe events. Means are adjusted by treatment and continuous baseline HbA1c.
Composite Endpoint of Occurrence of Treat to Target Efficacy Response, That is an HbA1c Under Treatment of <6.5% After 14 Weeks of Treatment, and no Occurrence of Moderate or Severe Metformin Pre-specified GI Side Effects Assessed by Investigators
The proportion of patients who achieved all the targets in a composite endpoint (HbA1c below 6.5% after 14 weeks of treatment; no occurrence of pre-specified moderate or severe GI side effects of metformin, as assessed by the investigators during 14 weeks of treatment).
Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 14 Weeks of Treatment)
The proportion of patients who achieved a relative efficacy response (HbA1c lowering by at least 0.5% after 14 weeks of treatment).
Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.8% After 14 Weeks of Treatment)
The proportion of patients who achieved a relative efficacy response (HbA1c lowering by at least 0.8% after 14 weeks of treatment).
Composite Endpoint of Occurence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 14 Weeks of Treatment) and no Occurence of Moderate and Severe Metformin Pre-specified GI Side Effects Assessed by the Investigators During 14 Weeks
The proportion of patients who achieved all the targets in a composite endpoint (HbA1c lowered by at least 0.5% after 14 weeks of treatment; no occurrence of pre-specified moderate or severe GI side effects of metformin, as assessed by the investigators during 14 weeks of treatment).
Change From Baseline in Body Weight by Visit at Week 14
Means are adjusted by treatment, continuous baseline HbA1c and continuous baseline weight
Composite Endpoint of Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.8% After 14 Weeks of Treatment) and no Occurrence of Moderate and Severe Metformin Pre-specified GI Side Effects Assessed by Investigators During 14 Weeks
The proportion of patients who achieved all the targets in a composite endpoint (HbA1c lowered by at least 0.8% after 14 weeks of treatment; no occurrence of pre-specified moderate or severe GI side effects of metformin, as assessed by the investigators during 14 weeks of treatment).
Change From Baseline in HbA1c Over Time
Means are adjusted by treatment and continuous baseline HbA1c

Full Information

First Posted
September 21, 2011
Last Updated
November 13, 2014
Sponsor
Boehringer Ingelheim
Collaborators
Eli Lilly and Company
search

1. Study Identification

Unique Protocol Identification Number
NCT01438814
Brief Title
Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Official Title
A Randomised, Double-blind, Double-dummy, Active-comparator Controlled Study Investigating the Efficacy and Safety of Linagliptin Co-administered With Metformin QD at Evening Time Versus Metformin BID Over 14 Weeks in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Study Type
Interventional

2. Study Status

Record Verification Date
November 2014
Overall Recruitment Status
Completed
Study Start Date
November 2011 (undefined)
Primary Completion Date
March 2013 (Actual)
Study Completion Date
March 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
Collaborators
Eli Lilly and Company

4. Oversight

5. Study Description

Brief Summary
The aim of this study is to investigate the impact of the combination therapy of linagliptin and metformin at submaximal doses in reduction of Glycosylated haemoglobin (HbA1c) and metformin pre-specified gastro-intestinal (GI) side effects in treatment naive patients of with type 2 diabetes mellitus.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
689 (Actual)

8. Arms, Groups, and Interventions

Arm Title
linagliptin + metformin
Arm Type
Experimental
Arm Description
patients to receive linagliptin +metformin QD
Arm Title
metformin
Arm Type
Active Comparator
Arm Description
patients to receive metformin BID
Intervention Type
Drug
Intervention Name(s)
metformin placebo
Intervention Description
metformin placebo tablets 500mg
Intervention Type
Drug
Intervention Name(s)
linagliptin placebo
Intervention Description
linagliptin placebo tablets 5mg
Intervention Type
Drug
Intervention Name(s)
metformin
Intervention Description
metformin tablets 500mg
Intervention Type
Drug
Intervention Name(s)
metformin
Intervention Description
metformin tablets 500 mg
Intervention Type
Drug
Intervention Name(s)
linagliptin
Intervention Description
linagliptin tablets 5mg
Primary Outcome Measure Information:
Title
Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) After 14 Weeks Treatment
Description
Adjusted mean change in HbA1c from baseline at Week 14 was analysed using an ANCOVA model. The Model included treatment and continuous baseline HbA1c.
Time Frame
Baseline and 14 weeks
Secondary Outcome Measure Information:
Title
Composite Endpoint of Occurrence of Treat to Target Efficacy Response, That is an HbA1c Under Treatment of <7.0% After 14 Weeks of Treatment, on no Occurrence of Moderate or Severe Gastrointestinal (GI) Side Effects During 14 Weeks of Treatment
Description
The proportion of patients who achieved all the targets in a composite endpoint (HbA1c below 7.0% after 14 weeks of treatment; no occurrence of pre-specified moderate or severe gastrointestinal (GI) side effects of metformin, as assessed by the investigators during 14 weeks of treatment)
Time Frame
14 weeks
Title
Occurence of Metformin Pre-specified Moderate to Severe GI Side Effects Assessed by Investigators During 14 Weeks of Treatment
Description
Proportion of patients who experienced at least one metformin pre-specified moderate or severe GI side effect during 14 weeks
Time Frame
14 weeks
Title
Change From Baseline in Fasting Plasma Glucose (FPG) After 14 Weeks of Treatment
Description
Means are adjusted by treatment, continuous baseline HbA1c and continuous baseline fasting plasma glucose.
Time Frame
Baseline and 14 weeks
Title
Metformin Pre-specified GI Symptom Intensity Score Assessed by Investigators During 14 Weeks of Treatment
Description
Patients could experience multiple events, therefore, multiple answers were possible for each patient.
Time Frame
14 weeks
Title
Metformin Pre-specified GI Symptom Intensity Score Assessed by Patients During 14 Weeks of Treatment
Description
The intensity of the GI side effects was also assessed by the patients using VAS scaled from 0 to 10; higher scores indicate more severe events. Means are adjusted by treatment and continuous baseline HbA1c.
Time Frame
14 weeks
Title
Composite Endpoint of Occurrence of Treat to Target Efficacy Response, That is an HbA1c Under Treatment of <6.5% After 14 Weeks of Treatment, and no Occurrence of Moderate or Severe Metformin Pre-specified GI Side Effects Assessed by Investigators
Description
The proportion of patients who achieved all the targets in a composite endpoint (HbA1c below 6.5% after 14 weeks of treatment; no occurrence of pre-specified moderate or severe GI side effects of metformin, as assessed by the investigators during 14 weeks of treatment).
Time Frame
14 weeks
Title
Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 14 Weeks of Treatment)
Description
The proportion of patients who achieved a relative efficacy response (HbA1c lowering by at least 0.5% after 14 weeks of treatment).
Time Frame
14 weeks
Title
Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.8% After 14 Weeks of Treatment)
Description
The proportion of patients who achieved a relative efficacy response (HbA1c lowering by at least 0.8% after 14 weeks of treatment).
Time Frame
14 weeks
Title
Composite Endpoint of Occurence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 14 Weeks of Treatment) and no Occurence of Moderate and Severe Metformin Pre-specified GI Side Effects Assessed by the Investigators During 14 Weeks
Description
The proportion of patients who achieved all the targets in a composite endpoint (HbA1c lowered by at least 0.5% after 14 weeks of treatment; no occurrence of pre-specified moderate or severe GI side effects of metformin, as assessed by the investigators during 14 weeks of treatment).
Time Frame
14 weeks
Title
Change From Baseline in Body Weight by Visit at Week 14
Description
Means are adjusted by treatment, continuous baseline HbA1c and continuous baseline weight
Time Frame
Baseline and 14 weeks
Title
Composite Endpoint of Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.8% After 14 Weeks of Treatment) and no Occurrence of Moderate and Severe Metformin Pre-specified GI Side Effects Assessed by Investigators During 14 Weeks
Description
The proportion of patients who achieved all the targets in a composite endpoint (HbA1c lowered by at least 0.8% after 14 weeks of treatment; no occurrence of pre-specified moderate or severe GI side effects of metformin, as assessed by the investigators during 14 weeks of treatment).
Time Frame
14 weeks
Title
Change From Baseline in HbA1c Over Time
Description
Means are adjusted by treatment and continuous baseline HbA1c
Time Frame
Baseline, 2 weeks and 8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Diagnosis of Type 2 diabetes mellitus (T2DM) prior to informed consent; Male and female patients on diet and exercise regimen who are drug naive, defined as absence of any oral antidiabetic therapy or insulin for 12 weeks prior to randomization Glycosylated haemoglobin A1c (HbA1c) >/= 7.0% (53 mmol/mol) to </= 10.0% (86 mmol/mol) at visit 1 (screening); Age>/=18 and </=80 years at visit 1(screening); Body Mass Index (BMI)</= 45kg/m2 at visit 1 (screening); Signed and dated written informed consent by date of visit 1 in accordance with Good Clinical Practice (GCP) and local legislation Exclusion criteria: Uncontrolled hyperglycaemia with a glucose level >240 mg/dl (13.3mmol/L) after an overnight fast during screening/placebo run-in and confirmed by a second measurement (Not on the same day); Treatment with any oral antidiabetic drug or insulin within 12 weeks prior to randomization Acute coronary syndrome (non-STEMI, STEMI and unstable angina pectoris),stroke or Transient ischemia attack (TIA) within 3 months prior to informed consent; Indication of liver disease/Impaired hepatic function, defined by serum levels of either Aspartate aminotransferase (ALT or SGPT), alanine aminotransferase (AST or SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at visit 1 and/or run-in phase, Impaired renal function, defined as eGFR< 60ml/min (moderate or severe renal impairment, modification of diet in renal disease (MDRD) formula) as determined during screening or at run-in phase Bariatric surgery within the past two years and other gastrointestinal surgeries that induced chronic malabsorption Medical history of Cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years Blood dyscrasia or any other disorders causing haemolysis or unstable Red Blood Cell (eg. malaria, babesiosis, haemolytic anemia) Known history of pancreatitis and chronic pancreatitis Contraindications to metformin according to the local label Treatment with anti-obesity drugs 3 months prior to informed consent or any other treatment at the time of screening (i.e. surgery, aggressive diet regimen etc) leading to unstable body weight Current treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent or any other uncontrolled endocrine disorder except T2DM Pre-menopausal women (last menstruation less than 1 year prior to informed consent) who: are nursing or pregnant or are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial or who do not agree to continue contraception for at least 30 days after the last dose of study drug. Acceptable methods of birth control include tubal ligation, transdermal patch, intra-uterine devices/systems(IUDs/IUSs), oral, implantable, or injectable contraceptives, complete sexual abstinence (if acceptable by local authorities), double barrier method and vasectomized partner. Alcohol or drug abuse within 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study drug intake Participation in another trial with application of any investigational drug within 30 days prior to informed consent Any other clinical condition that would jeopardize patients safety while participating in this trial
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
1218.60.90001 Boehringer Ingelheim Investigational Site
City
Dhaka
Country
Bangladesh
Facility Name
1218.60.90002 Boehringer Ingelheim Investigational Site
City
Dhaka
Country
Bangladesh
Facility Name
1218.60.90003 Boehringer Ingelheim Investigational Site
City
Dhaka
Country
Bangladesh
Facility Name
1218.60.32001 Boehringer Ingelheim Investigational Site
City
Genk
Country
Belgium
Facility Name
1218.60.32005 Boehringer Ingelheim Investigational Site
City
Ham
Country
Belgium
Facility Name
1218.60.32002 Boehringer Ingelheim Investigational Site
City
Hasselt
Country
Belgium
Facility Name
1218.60.32004 Boehringer Ingelheim Investigational Site
City
Natoye
Country
Belgium
Facility Name
1218.60.32003 Boehringer Ingelheim Investigational Site
City
Tremelo
Country
Belgium
Facility Name
1218.60.20009 Boehringer Ingelheim Investigational Site
City
Calgary
State/Province
Alberta
Country
Canada
Facility Name
1218.60.20003 Boehringer Ingelheim Investigational Site
City
Burnaby
State/Province
British Columbia
Country
Canada
Facility Name
1218.60.20014 Boehringer Ingelheim Investigational Site
City
Coquitlam
State/Province
British Columbia
Country
Canada
Facility Name
1218.60.20010 Boehringer Ingelheim Investigational Site
City
Surrey
State/Province
British Columbia
Country
Canada
Facility Name
1218.60.20004 Boehringer Ingelheim Investigational Site
City
Halifax
State/Province
Nova Scotia
Country
Canada
Facility Name
1218.60.20012 Boehringer Ingelheim Investigational Site
City
Corunna
State/Province
Ontario
Country
Canada
Facility Name
1218.60.20015 Boehringer Ingelheim Investigational Site
City
Hamilton
State/Province
Ontario
Country
Canada
Facility Name
1218.60.20006 Boehringer Ingelheim Investigational Site
City
London
State/Province
Ontario
Country
Canada
Facility Name
1218.60.20013 Boehringer Ingelheim Investigational Site
City
London
State/Province
Ontario
Country
Canada
Facility Name
1218.60.20002 Boehringer Ingelheim Investigational Site
City
Sarnia
State/Province
Ontario
Country
Canada
Facility Name
1218.60.20011 Boehringer Ingelheim Investigational Site
City
Sarnia
State/Province
Ontario
Country
Canada
Facility Name
1218.60.20005 Boehringer Ingelheim Investigational Site
City
Strathroy
State/Province
Ontario
Country
Canada
Facility Name
1218.60.20007 Boehringer Ingelheim Investigational Site
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
1218.60.20016 Boehringer Ingelheim Investigational Site
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
1218.60.20001 Boehringer Ingelheim Investigational Site
City
St-Romuald
State/Province
Quebec
Country
Canada
Facility Name
1218.60.86001 Boehringer Ingelheim Investigational Site
City
Beijing
Country
China
Facility Name
1218.60.86003 Boehringer Ingelheim Investigational Site
City
Beijing
Country
China
Facility Name
1218.60.86011 Boehringer Ingelheim Investigational Site
City
Changsha
Country
China
Facility Name
1218.60.86012 Boehringer Ingelheim Investigational Site
City
Chengdu
Country
China
Facility Name
1218.60.86010 Boehringer Ingelheim Investigational Site
City
Chongqing
Country
China
Facility Name
1218.60.86013 Boehringer Ingelheim Investigational Site
City
Hubei
Country
China
Facility Name
1218.60.86014 Boehringer Ingelheim Investigational Site
City
Hubei
Country
China
Facility Name
1218.60.86006 Boehringer Ingelheim Investigational Site
City
Nanjing
Country
China
Facility Name
1218.60.86007 Boehringer Ingelheim Investigational Site
City
Nanjing
Country
China
Facility Name
1218.60.86005 Boehringer Ingelheim Investigational Site
City
Shanghai
Country
China
Facility Name
1218.60.86009 Boehringer Ingelheim Investigational Site
City
Shenyang
Country
China
Facility Name
1218.60.86008 Boehringer Ingelheim Investigational Site
City
Wuxi
Country
China
Facility Name
1218.60.49007 Boehringer Ingelheim Investigational Site
City
Berlin
Country
Germany
Facility Name
1218.60.49008 Boehringer Ingelheim Investigational Site
City
Berlin
Country
Germany
Facility Name
1218.60.49005 Boehringer Ingelheim Investigational Site
City
Dresden
Country
Germany
Facility Name
1218.60.49004 Boehringer Ingelheim Investigational Site
City
Erfurt
Country
Germany
Facility Name
1218.60.49006 Boehringer Ingelheim Investigational Site
City
Frankfurt
Country
Germany
Facility Name
1218.60.49003 Boehringer Ingelheim Investigational Site
City
Hamburg
Country
Germany
Facility Name
1218.60.49002 Boehringer Ingelheim Investigational Site
City
Neuwied
Country
Germany
Facility Name
1218.60.49001 Boehringer Ingelheim Investigational Site
City
Unterschneidheim
Country
Germany
Facility Name
1218.60.50001 Boehringer Ingelheim Investigational Site
City
Guatemala
Country
Guatemala
Facility Name
1218.60.50002 Boehringer Ingelheim Investigational Site
City
Guatemala
Country
Guatemala
Facility Name
1218.60.50003 Boehringer Ingelheim Investigational Site
City
Guatemala
Country
Guatemala
Facility Name
1218.60.85001 Boehringer Ingelheim Investigational Site
City
Hong Kong
Country
Hong Kong
Facility Name
1218.60.85002 Boehringer Ingelheim Investigational Site
City
Hong Kong
Country
Hong Kong
Facility Name
1218.60.91004 Boehringer Ingelheim Investigational Site
City
Aurangabad
Country
India
Facility Name
1218.60.91010 Boehringer Ingelheim Investigational Site
City
Bangalore
Country
India
Facility Name
1218.60.91005 Boehringer Ingelheim Investigational Site
City
Coimbatore
Country
India
Facility Name
1218.60.91008 Boehringer Ingelheim Investigational Site
City
Kolkata
Country
India
Facility Name
1218.60.91001 Boehringer Ingelheim Investigational Site
City
Nagpur
Country
India
Facility Name
1218.60.91007 Boehringer Ingelheim Investigational Site
City
Nagpur
Country
India
Facility Name
1218.60.91003 Boehringer Ingelheim Investigational Site
City
Pune
Country
India
Facility Name
1218.60.91006 Boehringer Ingelheim Investigational Site
City
Pune
Country
India
Facility Name
1218.60.96001 Boehringer Ingelheim Investigational Site
City
Beirut
Country
Lebanon
Facility Name
1218.60.96002 Boehringer Ingelheim Investigational Site
City
Beirut
Country
Lebanon
Facility Name
1218.60.96004 Boehringer Ingelheim Investigational Site
City
Byblos
Country
Lebanon
Facility Name
1218.60.96003 Boehringer Ingelheim Investigational Site
City
Hazmieh
Country
Lebanon
Facility Name
1218.60.96005 Boehringer Ingelheim Investigational Site
City
Saida
Country
Lebanon
Facility Name
1218.60.52005 Boehringer Ingelheim Investigational Site
City
Aguascalientes
Country
Mexico
Facility Name
1218.60.52003 Boehringer Ingelheim Investigational Site
City
Cuernavaca
Country
Mexico
Facility Name
1218.60.52001 Boehringer Ingelheim Investigational Site
City
Durango
Country
Mexico
Facility Name
1218.60.52002 Boehringer Ingelheim Investigational Site
City
Durango
Country
Mexico
Facility Name
1218.60.52004 Boehringer Ingelheim Investigational Site
City
Monterrey
Country
Mexico
Facility Name
1218.60.51001 Boehringer Ingelheim Investigational Site
City
Lima
Country
Peru
Facility Name
1218.60.51002 Boehringer Ingelheim Investigational Site
City
Lima
Country
Peru
Facility Name
1218.60.51004 Boehringer Ingelheim Investigational Site
City
Piura
Country
Peru
Facility Name
1218.60.63001 Boehringer Ingelheim Investigational Site
City
Cebu City, Philippines
Country
Philippines
Facility Name
1218.60.63004 Boehringer Ingelheim Investigational Site
City
Iloilo City, Philippines
Country
Philippines
Facility Name
1218.60.63003 Boehringer Ingelheim Investigational Site
City
Manila
Country
Philippines
Facility Name
1218.60.63002 Boehringer Ingelheim Investigational Site
City
Marikina City, Philippines
Country
Philippines
Facility Name
1218.60.63005 Boehringer Ingelheim Investigational Site
City
Quezon City
Country
Philippines
Facility Name
1218.60.34001 Boehringer Ingelheim Investigational Site
City
Barcelona
Country
Spain
Facility Name
1218.60.34002 Boehringer Ingelheim Investigational Site
City
Barcelona
Country
Spain
Facility Name
1218.60.34003 Boehringer Ingelheim Investigational Site
City
Barcelona
Country
Spain
Facility Name
1218.60.34004 Boehringer Ingelheim Investigational Site
City
Barcelona
Country
Spain
Facility Name
1218.60.34006 Boehringer Ingelheim Investigational Site
City
Borges del Camp- Tarragona
Country
Spain
Facility Name
1218.60.34005 Boehringer Ingelheim Investigational Site
City
Centelles
Country
Spain
Facility Name
1218.60.34009 Boehringer Ingelheim Investigational Site
City
Granada
Country
Spain
Facility Name
1218.60.34008 Boehringer Ingelheim Investigational Site
City
L'Hospitalet de Llobregat
Country
Spain
Facility Name
1218.60.34007 Boehringer Ingelheim Investigational Site
City
MatarĂ³
Country
Spain
Facility Name
1218.60.34010 Boehringer Ingelheim Investigational Site
City
Valencia
Country
Spain
Facility Name
1218.60.88006 Boehringer Ingelheim Investigational Site
City
Chiayi County
Country
Taiwan
Facility Name
1218.60.88003 Boehringer Ingelheim Investigational Site
City
Kaohsiung,
Country
Taiwan
Facility Name
1218.60.88001 Boehringer Ingelheim Investigational Site
City
Taichung
Country
Taiwan
Facility Name
1218.60.88007 Boehringer Ingelheim Investigational Site
City
Taichung
Country
Taiwan
Facility Name
1218.60.88002 Boehringer Ingelheim Investigational Site
City
Tainan,
Country
Taiwan
Facility Name
1218.60.88004 Boehringer Ingelheim Investigational Site
City
Taipei County
Country
Taiwan

12. IPD Sharing Statement

Citations:
PubMed Identifier
25805187
Citation
Ji L, Zinman B, Patel S, Ji J, Bailes Z, Thiemann S, Seck T. Efficacy and safety of linagliptin co-administered with low-dose metformin once daily versus high-dose metformin twice daily in treatment-naive patients with type 2 diabetes: a double-blind randomized trial. Adv Ther. 2015 Mar;32(3):201-15. doi: 10.1007/s12325-015-0195-3. Epub 2015 Mar 25.
Results Reference
derived
Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1218/1218.60_U13-2724-01.pdf
Description
Related Info

Learn more about this trial

Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control

We'll reach out to this number within 24 hrs